Immunotherapy combo may boost rectal cancer treatment
NCT ID NCT07686640
First seen Jul 07, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This phase III trial is testing whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy after short-course radiation can improve outcomes for people with a specific type of locally advanced rectal cancer (pMMR/MSS). Participants receive either the standard treatment or the standard plus immunotherapy. The main goal is to see if the combination leads to a higher rate of complete tumor disappearance, either after surgery or during a watch-and-wait period. The study also tracks long-term survival and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- iparomlimab and tuvonralimab (immunotherapy drugs)
- What this could lead to
- If successful, this could offer a more effective treatment option for people with a common type of rectal cancer, potentially increasing the chance of a complete response and avoiding surgery.
- What could go wrong
- This is an early-stage trial with a relatively small number of participants. The immunotherapy combination may cause significant side effects, and it is not yet known if it will improve long-term survival or relapse rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Cancer Hospital and Institute
Jinan, Shandong, 0531, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding chemo after radiation help older adults with rectal cancer avoid surgery?
- Can a video call replace a clinic visit for cancer patients on radiotherapy?
- Can a common muscle relaxant make radiation deadlier for rectal cancer?
- Triple therapy takes on rare, aggressive kidney cancer
- Bladder cancer drug delivered directly: a new hope for BCG failures
- Breast reconstruction after mastectomy: which approach leads to happier patients?